Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
about
Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporterNeuregulin 1 and susceptibility to schizophrenia.Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaDe novo protein sequence analysis of Macaca mulattaDopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.Drug Design for CNS Diseases: Polypharmacological Profiling of Compounds Using Cheminformatic, 3D-QSAR and Virtual Screening MethodologiesN-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's diseaseNeuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophreniaCharacterizing thalamo-cortical disturbances in schizophrenia and bipolar illnessEmotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanismsActivation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake ratsThe adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted ratManganese exposure inhibits the clearance of extracellular GABA and influences taurine homeostasis in the striatum of developing ratsrTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortexSchizophrenia genes, gene expression, and neuropathology: on the matter of their convergenceAntipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotectionEarly somatosensory processing in individuals at risk for developing psychoses.Blockade of growth hormone secretagogue receptor 1A signaling by JMV 2959 attenuates the NMDAR antagonist, phencyclidine-induced impairments in prepulse inhibitionSex differences in animal models of psychiatric disorders.Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.Is lead exposure in early life an environmental risk factor for Schizophrenia? Neurobiological connections and testable hypotheses.GABA neurons in the ventral tegmental area responding to peripheral sensory input.Sex-dependent antipsychotic capacity of 17β-estradiol in the latent inhibition model: a typical antipsychotic drug in both sexes, atypical antipsychotic drug in males.Frontal-striatal-thalamic mediodorsal nucleus dysfunction in schizophrenia-spectrum patients during sensorimotor gating.MRI anatomy of schizophrenia.Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.The extended amygdala and the dopamine system: another piece of the dopamine puzzle.Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.Altered striatal functional connectivity in subjects with an at-risk mental state for psychosisDrugs for a new millennium.Regional localization of dopamine and ionotropic glutamate receptor subtypes in striatolimbic brain regions.Pathological correlations between traumatic brain injury and chronic neurodegenerative diseases.Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.Monoaminergic synapses and schizophrenia: 45 years of neuroleptics.NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia.Corticostriatal functional interactions in Parkinson's disease: a rTMS/[11C]raclopride PET studyHigh-frequency stimulation of the subthalamic nucleus modifies the expression of vesicular glutamate transporters in basal ganglia in a rat model of Parkinson's diseaseSelective augmentation of striatal functional connectivity following NMDA receptor antagonism: implications for psychosis.Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia.Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory
P2860
Q24555193-03888188-C86D-4240-A142-F7E4AAD27F5CQ24616921-B67A0FC5-B856-406C-9709-582DDAA0CF68Q24646206-58206246-03FB-42E1-AF88-35A0CBA5FA28Q24670134-ADD9E8A5-7CBA-416E-9DA4-0E13B55A2182Q24815335-1D0189A7-7C82-4B89-A442-C728A2BAD169Q26745421-4D946895-217E-4733-A1B4-BFF6BED8F79FQ26825619-24A88039-EF50-4BC0-AB1B-F26BDF9871B5Q27026382-270D4945-8D0F-4776-BC41-38F8DFA3351AQ27303206-BCB74EFA-140D-4528-8E88-5D909C333F73Q28073684-6E0459C3-51A1-4E3C-83AC-B885DA9FE67EQ28297687-C8C006B4-5F39-41DF-A7ED-8A7288882E46Q28343807-BDD747F8-45EE-4249-8C1A-B088C42D4615Q28384350-062EEF9C-4C14-4276-AC43-1C24B112305FQ28475974-6303131A-ECE0-4F52-A095-05306CFBC70EQ29618819-E5A0D13F-1038-409D-83F2-06E071F3A405Q30386608-4C372634-4C5A-4645-8B57-4C2512A13E28Q30390556-4512DDE4-D6A6-40FC-8385-6DCC0166EA0BQ30400548-F43A05D7-75A0-4B9A-A7B3-02D8E77BB7A5Q30401732-423EFD17-756F-4CD4-8B6A-2C65246BD33AQ30426586-068641BC-0C3B-4F3C-B3EC-A4D97C9C5112Q30454141-06745CF9-6979-40E1-BFF6-F47CFAC89DCFQ30459838-FB7E527A-592E-4F7C-B991-AC149E2B39B2Q30474007-C63FA1B5-5554-4535-887C-B9BEF0E5781DQ30487259-08229DCA-6434-46F0-A64A-48C6196CF2B8Q30577334-2351643E-C55B-426B-8E20-982D982CD2CFQ30993265-93C6252A-7814-4B99-9AF8-8484ADFD5A4AQ33338648-59F65BB7-23BE-4F4F-9C56-C377D88D285AQ33350202-69CC1EC4-0CE5-47E5-B27B-61A2D1B0ADF5Q33762485-F03F4F81-1F91-43B8-B883-9CA0E14BFDE6Q33835253-8A0FA2B6-1391-4888-8CE1-77922D920FA9Q33866762-73992CDF-F914-4A05-8DBC-313368D41AC5Q33891870-0A415905-CA36-4FF4-977F-B82EAA31A5C2Q33936354-0FA18110-6B01-478B-A9DA-9FB97BC3E12DQ34013426-6BFA026A-A816-41E7-A9D3-1BF5290BF619Q34149624-C96C55FD-014C-49D1-A242-EF4D1925F963Q34258327-25D0AD1D-D53E-4EDF-AB86-DE8892D51201Q34524675-00B9263F-85DD-49D2-B166-546A9752DCA2Q34579973-3411CA0E-7202-4D35-8F2C-925CCEA16E12Q34926526-EAB1A4B3-76E2-44F8-ADD1-0E0958C8458BQ35042195-15F421C1-45E2-471F-A950-45C33A36FD73
P2860
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Interactions between glutamate ...... renia and Parkinson's disease.
@ast
Interactions between glutamate ...... renia and Parkinson's disease.
@en
type
label
Interactions between glutamate ...... renia and Parkinson's disease.
@ast
Interactions between glutamate ...... renia and Parkinson's disease.
@en
prefLabel
Interactions between glutamate ...... renia and Parkinson's disease.
@ast
Interactions between glutamate ...... renia and Parkinson's disease.
@en
P1476
Interactions between glutamate ...... renia and Parkinson's disease.
@en
P2093
Carlsson A
Carlsson M
P304
P356
10.1016/0166-2236(90)90108-M
P577
1990-07-01T00:00:00Z